Claims
- 1. A method of separating a cell-containing sample into a substantially cell-depleted portion, and a cell-containing portion comprising at least one of a stem cell, a lymphocyte, and a leukocyte, comprising:
receiving the sample in a vessel, wherein the vessel retains the sample within a plurality of confining walls, and wherein at least one of the confining walls is flexible; providing an additive and magnetic particles, wherein the additive binds to the at least one of the stem cell, lymphocyte, and leukocyte, and the magnetic particles, and wherein the magnetic particles bind to the at least one of the stem cell, lymphocyte, and leukocyte, and the additive; combining the sample, the additive, and the magnetic particles to produce a cell-containing network; and separating the network within the plurality of confining walls from the cell-depleted portion by applying a first and a second force, wherein the first force is a magnetic force and the second force is an automatic mechanical force that is transmitted through at least one of the confining walls.
- 2. The method of claim 1 wherein cell-containing portion comprises a stem cell.
- 3. The method of claim 2 wherein the stem cell is selected from the group consisting of an embryonic stem cell, an adult stem cell, and a partially differentiated stem cell.
- 4. The method of claim 3 wherein the stem cell has a surface marker selected from the group consisting of SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81.
- 5. The method of claim 1 wherein cell-containing portion comprises a lymphocyte.
- 6. The method of claim 5 wherein the lymphocyte is selected from the group of a T-lymphocyte, a B-lymphocyte, a cytotoxic T-cell, a T-helper cell, and a natural killer cell.
- 7. The method of claim 6 wherein the lymphocyte has a surface marker selected from the group consisting of CD2, CD4, CD7, CD21, CD22, CD23, and CD16.
- 8. The method of claim 1 wherein the cell-containing portion comprises a leukocyte.
- 9. The method of claim 8 wherein the leukocyte is selected from the group of a thymocyte, a Langerhans histiocyte, and a dendritic cell.
- 10. The method of claim 9 wherein the leukocyte has a surface marker selected from the group consisting of CD1, CD33, CD45, and S100.
- 11. The method of claim 1 wherein the sample received in the vessel has a volume of between about 10 ml and 100 ml.
- 12. The method of claim 1 wherein the sample received in the vessel has a volume of between about 100 ml and 500 ml.
- 13. The method of claim 1 wherein the particles are coated with a coating.
- 14. The method of claim 13 wherein the coating comprises an anti-ligand.
- 15. The method of claim 13 wherein the coating comprises an antibody.
- 16. The method of claim 1 wherein the magnetic particles comprise a primary antibody and the additive comprises a secondary antibody, and wherein the primary antibody binds to a surface component of the at least one of the stem cell, lymphocyte, and leukocyte, and wherein the secondary antibody binds to the primary antibody.
- 17. The method of claim 1 wherein separating the network produces a separation efficiency of at least 90%.
- 18. The method of claim 1 wherein at least 90% by volume of the cell depleted portion is separated from the network within ten minutes, with a separation efficiency of at least 95%.
Parent Case Info
[0001] This application is a continuation-in-part of allowed U.S. patent application Ser. No. 09/514,686, filed Feb. 28, 2000 and claiming the benefit of U.S. patent application Ser. No. 09/261,068 filed Mar. 2, 1999, both of which are incorporated herein by reference herein.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09514686 |
Feb 2000 |
US |
Child |
09949314 |
Sep 2001 |
US |
Parent |
09261068 |
Mar 1999 |
US |
Child |
09949314 |
Sep 2001 |
US |